A discussion of the latest developments in the medical and dietary management of IBD.

Video Content:

00:00 - Intro/Welcome
04:27 - Discussing Benefits, Risks of Treatment, & Uncontrolled Disease with Patients.
05:08 - Starting with Crohn’s Disease
06:23 - CD Clinical Symptoms May Not Correlate with Intestinal Inflammation
08:10 - Skyrizi (Risankizumab) for Crohn’s Disease: An IL-23 Inhibitor
10:09 - Skyrizi (Clinical Remission at Week 52)
13:19 - Skyrizi (Fortify AEs)
16:16 - Skyrizi (Frequency of Dosing Convenience)
16:36 - New Drugs For Ulcerative Colitis: Zeposia & Rinvoq
17:42 - Disease Progression Necessitates Changes in UC Treatment
19:29 - Ulcerative Colitis: Sigmoidoscopy/Colonoscopy: What Does Inflammation Look Like?
20:17 - MAYO Endoscopy Subscores
21:59 - Zeposia (Ozanimod): A S1P Modulator
24:11 - Zeposia (Symptomatic Response & Remission)
25:22 - Zeposia (Control is Possible Without the use of Corticosteroids)
25:22 - Zeposia (Drug Discontinuation Rates Less Than Placebo)
28:03 - Rinvoq (Upadacitinib) for Ulcerative Colitis: A Jak-Kinase Inhibitor
29:44 - Rinvoq (Patient-Reported Outcomes Data by Day)
30:50 - Rinvoq (Clinical Remission at Week 8)
32:45 - Rinvoq (AEs of Special Interest)
34:57 - Treatment Summary
38:13 - Advances in the Role of Diet in IBD
41:53 - Fiber: Friend or Foe?
44:40 - Eternal Nutrition
46:10 - Recommended Dietary Patterns in CD & UC
48:16 - Specific Carbohydrate Diet (SCD)
49:52 - Mediterranean Diet
52:04 - Nutritional Takeaways
53:09 - Q&A

свернуть